Upfront Briefing
It’s Monday — and JPM week kicks off today, the sector’s biggest stage for capital + updates.
Sanofi picked up an EU approval for Teizeild in stage 2 type 1 diabetes, adding a fresh regulatory milestone to its diabetes stack.
In funding land, Teva and Royalty Pharma teamed up on up to $500M to accelerate a vitiligo program—less “raise more” and more “run faster.”
And the IPO inbox is getting crowded: Eikon Therapeutics filed, offering an early read on how real the biotech window is right now.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,966.3 |
0.6% |
1.8% |
| Nasdaq 100 |
25,766.3 |
1.0% |
2.0% |
| Russell 2000 |
2,624.2 |
0.8% |
5.7% |
| XBI (Biotech ETF) |
124.5 |
0.6% |
2.1% |
| Nasdaq Biotech |
5,817.4 |
0.2% |
1.9% |
| Clinical Trials ETF (BBC) |
39.6 |
1.3% |
2.6% |
|
- Biotech kept up with the broader risk-on tape: XBI 0.6% matched the S&P 500 0.6% on the day.
- BBC was the standout mover, up 1.3% and outpacing the Nasdaq 100’s 1.0% gain.
- Market data: U.S. close Fri 09-Jan-2026.
The Big 3
|
1
|
Sanofi's Teizeild approved in EU for stage 2 type 1 diabetes
|
-
Sanofi secured EU approval for Teizeild in stage 2 type 1 diabetes — a clean regulatory milestone that shifts the conversation from “can it clear” to “how does it launch” as JPM week kicks off.
-
Why it matters:
EU launch is a real commercial catalyst: it puts HTA/payers front-and-center on how to price “delay/progression” value, and sets up 2026 demand signals (label → reimbursement → early uptake cadence).
-
Source:
PR
|
|
2
|
Teva, Royalty Pharma fund vitiligo program up to $500M
|
-
Teva and Royalty Pharma struck a funding deal worth up to $500M to accelerate a vitiligo program — structured capital that prioritizes speed-to-data over a plain-vanilla raise.
-
Why it matters:
This is effectively a capital-plan de-risking: it funds speed (trial expansion / timelines) while limiting near-term equity dependence. Royalty’s involvement is a useful external read-through on perceived risk/reward and potential monetization paths.
-
Source:
PR
|
|
3
|
Eikon Therapeutics files for IPO
|
-
Eikon Therapeutics filed for an IPO — an early read on whether the 2026 biotech IPO window is truly reopening, not just selectively ajar.
-
Why it matters:
A “brand-name” S-1 is a live test of IPO appetite. Watch valuation expectations, cash runway/burn, and whether the book rewards platform narratives — because that resets comps for late-stage privates lining up behind it.
-
Source:
BioPharma Dive
-
More:
Endpoints
|
Everything Else that broke
- Idorsia's lucerastat Phase 3 Fabry data published in Nature Communications. — PR
- J&J reaches drug pricing, tariff deal with White House. — Endpoints
- Insmed Brinsupri sales beat lifts shares. — BioSpace
- Novartis to build fourth US radioligand therapy facility. — Endpoints
- uniQure schedules Type A FDA meeting for AMT-130 approval. — PR
- Alnylam outlines five-year plan as drug sales miss expectations. — STAT
- Krystal Biotech reports early findings for CF gene therapy. — BioCentury
- Biotech fundraising and new venture funds ahead of JPM. — Endpoints
- argenx highlights 2026 strategic priorities, 2025 sales. — PR
- FDA delays Stoke request for expedited epilepsy drug submission. — STAT
- InflaRx cuts staff by 30%, pivots priorities. — BioSpace
- Merck discusses plans to buffer Keytruda patent cliff. — Endpoints
Deal Flow
M&A / BD&L
- Roche and MediLink sign another ADC licensing deal (YL201 B7H3 ADC; $570M upfront/near-term milestones ex-China). — BioSpace
- Madrigal licenses ervogastat from Pfizer for MASH pipeline. — PR
- Speculation builds around Revolution Medicines deal. — BioSpace
VC / Private Financings
- Mirador raises $250M Series B, considers IPO. — Endpoints
- Orca Bio adds $250M financing for T cell therapy launch. — Endpoints
- AirNexis formed with $200M to advance China-derived COPD drug. — BioCentury
IPOs / Follow-Ons
- Eikon Therapeutics files for IPO. — BioPharma Dive
- Veradermics files for IPO. — Endpoints
- Bright Minds Biosciences closes $175M public offering. — PR
- Alumis closes upsized public offering with option exercise. — PR
- Aktis IPO debuts up 25%. — Endpoints
Academic Corner
- Reducing Tobacco Use Worldwide: Smokeless Tobacco and Oral Cancer in Global Perspective. — NEJM
|
